SCHEMBL15034141

SCHEMBL15034141

COc1cc(Cl)cc(C(=O)N2CCN(C(=O)c3ncn(-c4ccccc4)n3)C(C)(C)C2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.46
MAPT P10636 6/20 0.46
TP53 P04637 4/20 0.46
POLB P06746 3/20 0.46
CFTR P13569 1/20 0.41
ALDH1A1 P00352 5/20 0.38
KDM4E B2RXH2 3/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
HIF1A Q16665 2/20 0.38
MAPK1 P28482 2/20 0.38
CYP2C9 P11712 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
FFAR2 O15552 1/20 0.38
USP2 O75604 3/20 0.37
CYP1A2 P05177 2/20 0.37
CYP3A4 P08684 2/20 0.37
HPGD P15428 2/20 0.37
TSHR P16473 1/20 0.37
CYP2C19 P33261 1/20 0.37
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15034170 0.92 MAPT (0.42) SMN1; SMN2MAPTTP53POLBCFTR
SCHEMBL15034139 0.89 ALDH1A1 (0.47) SMN1; SMN2MAPTTP53POLBCFTR
SCHEMBL15034146 0.88 MAPT (0.39) SMN1; SMN2MAPTTP53POLBCFTR
SCHEMBL15020006 0.87 ALDH1A1 (0.44) SMN1; SMN2MAPTTP53POLBALDH1A1
SCHEMBL15034067 0.86 GRM5 (0.47) ALDH1A1L3MBTL1HPGD
SCHEMBL15034162 0.85 CYP3A4 (0.45) SMN1; SMN2MAPTTP53ALDH1A1HIF1A
SCHEMBL15034134 0.84 CFTR (0.44) SMN1; SMN2MAPTTP53POLBCFTR
SCHEMBL15034186 0.84 MAPT (0.43) SMN1; SMN2MAPTTP53POLBCFTR
SCHEMBL15034348 0.84 MAPT (0.42) SMN1; SMN2MAPTTP53POLBCFTR
SCHEMBL15034135 0.84 MAPT (0.49) SMN1; SMN2MAPTTP53POLBCFTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883789-B2 Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-11 US disclosed
US-8883789-B2 Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-11 US disclosed
US-20130158042-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-20 US disclosed
US-20130158042-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158042-A1 NOVEL COMPOUNDS GRM5, GRIK5, GRM1 SMN1; SMN2 2592/4885MAPT 270/4885TP53 3722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.